FYI: How to actually stop a GLP-1 without losing the progress.

So, Yesterday we covered the Fractyl procedure that might one day give you a one-time surgical off-ramp from GLP-1s. Today we cover the off-ramp that actually exists right now, and it's a playbook your doctor may not have walked you through.

Most people who stop a GLP-1 regain most of their weight within a year. That's the headline. What the headline misses is that the people who don't regain almost all had the same four-step protocol. We're going to walk through it.

This is Off Label, Not Medical Advice.

Let's go.

The Morning Read: The evidence-based playbook for stopping a GLP-1 without losing everything you gained.

Two studies dropped in March 2026 that should reframe how you think about stopping a GLP-1.

Study one. The Lancet's eClinicalMedicine journal published a meta-regression by Wills et al. on March 4, 2026, pulling together every randomized controlled trial that followed patients after they stopped a GLP-1. The headline number: at 1 year post-discontinuation, patients regained an average of 60% of the weight they lost during treatment. The trajectory is nonlinear, fast at first, then it plateaus. The plateau sits below baseline weight, meaning some benefit persists indefinitely. But 60% is the number to remember.

Study two. Cleveland Clinic published a real-world cohort study of nearly 8,000 adults in Diabetes, Obesity and Metabolism on March 12, 2026. They tracked actual patients who stopped GLP-1s in clinical practice. The result: 45% of obesity patients maintained or kept losing weight in the year after stopping. In the diabetes group, 56% maintained. The trial number says you're going to regain. The real-world number says it depends on what you do next.

The difference between those two groups is the whole game. People who stop and do nothing regain. People who stop with a plan don't.

NPR reported on April 15, 2026 that fewer than 1 in 4 patients remain on a GLP-1 after 1 year per a JAMA research letter from Dr. Jaime Almandoz at UT Southwestern. The vast majority of GLP-1 users are going to be in this conversation eventually. Today is the protocol.

The single biggest mistake is treating "stopping the drug" like flipping a switch. Semaglutide has a half-life of about a week. It takes roughly five weeks for the drug to fully clear your system. If you stop on a Monday, you are going to feel relatively normal for a few weeks, then your appetite is going to come back hard while your metabolism is still slow. Hunger surging plus slow metabolism equals the rebound everyone fears.

The TAILGATE study (Embla, presented at the European Congress on Obesity 2024 in Venice) is the best real-world evidence we have. 2,246 Danish patients in a structured weight management program. 353 of them tapered to zero. Average taper duration: 9.9 weeks. Of the 240 who completed the taper, follow-up data on 85 patients showed they actually lost an additional 1.5% of body weight at 26 weeks post-cessation. Not regained. Lost more.

The protocol that worked: stepwise dose reduction every few weeks, while continuing structured lifestyle support.

A reasonable framework based on TAILGATE plus the Oxford Academic clinical guidance (September 2025):

If you're on Wegovy 2.4 mg weekly, reduce to 1.7 mg for 4 to 6 weeks, then 1.0 mg for 4 to 6 weeks, then 0.5 mg for 4 to 6 weeks, then stop if your weight has been stable (less than 2% regain) throughout. Total taper duration: 12 to 18 weeks. ThedaCare and Mayo Clinic clinicians describe a similar 2-month protocol with weekly check-ins.

The biological reason this works: your body's natural satiety hormones (PYY, leptin, ghrelin) need time to recalibrate as the GLP-1 levels drop. Cold turkey skips that recalibration. A taper gives those systems time to come back online.

This is non-negotiable, on the drug and after.

The 2026 International Journal of Obesity commentary by Spreckley et al. recommends 1.2 to 1.6 grams of protein per kilogram of total body weight, drawing on bariatric surgery protocols. Newer 2026 work (Barana, Urbina) targets 1.5 grams per kilogram of fat-free mass. Translated for most adults: somewhere between 80 and 130 grams of protein per day, distributed as 25 to 30 grams per meal.

Why per meal matters: your body can only use so much protein at once for muscle protein synthesis. One 100-gram protein bomb at dinner does less than four 25-gram doses across the day.

Best sources: lean meats, eggs, dairy, whey protein for the leucine content (the amino acid that triggers muscle building).

Resistance training: 2 to 3 sessions per week minimum, compound movements (squats, lunges, rows, deadlifts, push-ups), 8 to 12 reps per set, 2 to 3 sets per exercise. The 2026 Frontiers in Clinical Diabetes review and multiple 2025-2026 case series confirm: this single intervention alone cuts lean mass loss nearly in half.

Add creatine monohydrate, 3 to 5 grams daily. The 2023 Sports Medicine paper by Candow et al. shows consistent lean mass preservation in caloric deficit conditions. It's $20 a month at the supplement store.

The math: if you lose 50 pounds and 40% comes from muscle (the worst-case scenario without protein and lifting), you've lost 20 pounds of muscle. When you stop the drug, fat comes back faster than muscle does. You end up with a worse body composition than when you started, even if the scale reads similar. That's the trap. Protein and lifting are how you avoid it.

This is the buried part of the playbook nobody talks about.

A 2024 study by Paddu et al. published in Obesity (the journal) tracked 105 patients at Vanderbilt who completed 12 months of GLP-1 therapy and then transitioned to generic anti-obesity medications. Of the 40 patients who needed maintenance support, the prescription patterns were:

Average 1.7 generic agents per patient during maintenance. Patients maintained weight loss for up to 24 months on this combination approach. Average sustained reduction: 23.1 kilograms from 99.5 to 76.4 kg, BMI reduced 8.6 points.

These drugs are decades old. Cheap. Generic. Well-tolerated. Metformin is roughly $4 per month. Topiramate is around $10. Bupropion is around $15. The total maintenance stack costs less than a single Wegovy injection.

No drug company is marketing this playbook to you. There's no profit in a $4 generic. Telehealth platforms aren't building businesses on it. But it works, it's documented in peer-reviewed data, and it's one of the most under-utilized strategies in post-GLP-1 care.

If your insurance drops your GLP-1, if you can't afford it anymore, or if you just want to step down to something simpler, this is the conversation to have with your doctor. Bring the Paddu paper if you have to.

The honest reality from the Kantar survey reported by NPR: 74% of GLP-1 stoppers say they are likely or very likely to restart. Cycling on and off is the actual real-world pattern. The medical framing of "stopping = failure" doesn't match how patients are using these drugs.

If you're going to cycle, do it on purpose, not by accident. The restart triggers from the literature:

A note on cycling: Dr. Jaime Almandoz at UT Southwestern warned via NPR that repeated stop-start cycles may compound muscle loss because each restart begins from a worse body composition baseline. Dr. Ian Neeland at Case Western counters that GLP-1s may improve muscle quality even while reducing quantity. The science isn't settled. What is settled: protein and resistance training are non-negotiable on AND off the drug if you plan to cycle.

Three things most patients don't know.

Buried inside the TAILGATE study is the detail almost nobody quotes: those 2,246 Danish patients achieved 14.8% weight loss at 64 weeks while using only 36.1% of the standard cumulative semaglutide dose that titration protocols would have prescribed. Average max dose was 0.77 mg, not the 2.0 to 2.4 mg most US patients are titrated to.

If lower doses work, side effects are lower, cost is lower, and the eventual taper is smoother because you're stepping down from a lower peak. Most US clinicians still default to maximum titration by the manufacturer's schedule. The TAILGATE data suggests that's unnecessary for many patients.

The UK's National Institute for Health and Care Excellence recommends that semaglutide be prescribed for weight loss for a maximum duration of 2 years. No such limit on tirzepatide yet. American obesity medicine almost universally frames GLP-1s as lifetime therapy. NICE doesn't agree. At least one major developed-world regulator built discontinuation into the standard of care.

That's a regulatory acknowledgment that stopping is normal and expected, not a failure.

The single most important finding in the March 2026 Cleveland Clinic study: 45% of real-world obesity patients maintained weight in the year after stopping. Not 33%. Not 18%. Forty-five percent. The trial data underestimates real-world outcomes because real patients don't just stop and do nothing. They switch medications. They double down on lifestyle. They restart later if they need to. They build a system.

The trial narrative is "stopping = catastrophe." The real-world narrative is "stopping with a plan = workable for nearly half of patients."

Text your doctor this: "I'm thinking about tapering off my GLP-1 and want to avoid the average 60% regain seen in the recent Lancet meta-analysis. Can we build a plan that includes a stepwise dose reduction over about 2 months, a protein target of 1.2 to 1.6 grams per kg body weight, resistance training 2 to 3 times per week, and whether a generic bridge medication like metformin, topiramate, or bupropion would make sense as I come off? I'd also like to know the triggers that would mean I should pause the taper or restart."

Copy, paste, send.

The "Ozempic forever" narrative is starting to soften. Drug companies positioned GLP-1s as chronic-disease therapy from day one. That framing is not wrong, but it serves Novo and Lilly's revenue more than it serves patient choice. The TAILGATE low-dose data, the NICE 2-year cap, and the Cleveland Clinic real-world maintenance number all point toward a more nuanced reality.

Telehealth platforms are quietly building tapering services. WeightWatchers, Found, Noom, Sequence, and Ro all have post-discontinuation protocols in development. The retention math is simple: keeping a patient on a $99 monthly compounded maintenance dose is more profitable than losing them entirely.

Compounded GLP-1 access is tightening. FDA enforcement continues to narrow the 503A compounding pharmacy market. Compounded tirzepatide is largely unavailable as of April 2026 (shortage declaration ended late 2025). Compounded semaglutide is still available at $99 to $269 per month, but sources are fewer.

Wegovy got a list price reduction in early 2026. It mostly didn't help. Insurance copays are formulary-driven, not list-price-driven. Cash-pay patients still pay more than compounded options. The price drop was strategic positioning against tirzepatide and Foundayo, not patient relief.

Watch this: the maintenance medication category that obesity medicine is quietly rediscovering. Generic metformin (around $4 per month), topiramate (around $10), and bupropion (around $15) are cheap, well-tolerated, and have decades of safety data. The Vanderbilt Paddu et al. study in Obesity (2024) showed these generic combinations maintained weight for up to 24 months after GLP-1 discontinuation. No drug maker is marketing this playbook because there's no profit in a $4 generic. Ask your doctor about it anyway.

Tomorrow: The "lifetime use" framing isn't medical consensus, it's drug company spin. UK regulators have a 2-year cap. The TAILGATE data shows low doses work. Real-world maintenance is higher than the trial data suggests. We're going to walk through why "you have to take this forever" is the wrong default.

Hit reply and tell us what you want us to cover. Every reply is read. Story tips: [email protected]

See you in your inbox.

— Off Label

This is Off Label, Not Medical Advice. Content is for informational purposes only. Always consult a qualified healthcare provider before making medical decisions about starting, stopping, switching, or tapering GLP-1 medications or any other prescription drug.